医学
类风湿性关节炎
阿巴塔克普
内科学
间质性肺病
观察研究
前瞻性队列研究
肺
胃肠病学
关节炎
免疫病理学
痹症科
呼吸道疾病
情感(语言学)
外科
随机对照试验
队列研究
疾病严重程度
作者
Caterina Vacchi,Marco Sebastiani,Antonio Carletto,Elisa Bellis,Laura Cometi,Vincenzo Venerito,Maria Letizia Currò,Antonio Carriero,Roberta Foti,Mariagrazia Catanoso,Ennio Giulio Favalli,Chiara Bazzani,Francesca Cozzini,Andrea Morciano,Annamaria Iagnocco,Serena Guiducci,Florenzo Iannone,Fabiola Atzeni,Salvatore D’Angelo,Fabrizio Pancaldi
标识
DOI:10.55563/clinexprheumatol/yvkk4n
摘要
OBJECTIVES: The aim of this prospective multicentre observational study was to evaluate the clinical course and the incidence of interstitial lung disease (ILD) on a population affected with rheumatoid arthritis (RA). METHODS: Three hundred and twenty-five consecutive RA patients with an ongoing treatment with abatacept were enrolled in the study and followed for 24 months. At the enrolment, ILD was recorded in 20.6% of cases. Patients with ILD were followed according to the current clinical practice, while in patients without ILD, a careful assessment for respiratory symptoms and velcro crackles, also by mean of digital tools, was performed every six months. In this regard, each patient was evaluated by mean of VECTOR, a software able to identify velcro crackles with a diagnostic accuracy of 83.9% and a sensitivity of 93.2% in RA patients. RESULTS: During the study, no patients discontinued abatacept for a worsening of lung function, and no difference was recorded in two-year retention rate of abatacept between patients with and without ILD. After 24 months, ILD improved or remained stable in more than 85% of cases, while a worsening of radiologic picture was recorded in 14.9% of cases, mainly with usual interstitial pneumonia. Finally, the incidence rate of new-onset ILD was 0.39/100 patients/year. CONCLUSIONS: In conclusion, the presence of ILD did not affect the retention rate of the drug, suggesting a role for abatacept in the treatment of RA-ILD.
科研通智能强力驱动
Strongly Powered by AbleSci AI